New 2,2'-[(5,5'-(butane-1,4-diyl)bis(4-phenyl-4H-1,2,4-triazole-5,3-diyl))bis(sulfanediyl))bis(N-o-tolyl acetamide] 3a, 2,2'-[(5,5'-(butane-1,4-diyl)bis(4-phenyl-4H-1,2,4-triazole-5,3-diyl))bis(sulfanediyl))bis(N-3-bromophenyl)acetamide) 3b and 2,2'-[(5,5'-(butane-1,4-diyl)bis(4-phenyl-4H-1,2,4-triazole-5,3-diyl))bis(sulfanediyl)bis(N-benzylacetamide] 3c were synthetized via the reaction of 5,5'-(butane-1,4-diyl)bis(4-phenyl-4H-1,2,4-triazole-3-thiol) (1) with 2-chloro-N-(o-tolyl)acetamides 2a, 2-chloro-N-(m-bromophenyl)acetamide 2b and 2-chloro-N-(benzy)acetamide 2c, respectively. Target compounds were synthesized using phase transfer catalysis technique. The solid phase was potassium carbonate and the organic layer was dioxane while the catalyst is tetrabutyl ammonium bromide. Phase transfer catalysis (PTC) has the potential to enhance yields, shorten reaction times, eliminate the need for hazardous or costly reagents and solvents, and offer various additional advantages to manufacturers in the organic chemical sector. 1,2,4-Triazoles exhibit a broad spectrum of biological activities, including antifungal, antibacterial, anti-inflammatory, anticancer, antitubercular, antioxidant, antiviral, antidiabetic, analgesic and anticonvulsant properties. Therefore, the prepared compounds 3a-c are expected to have significant biological activities. Reaction of compound 1 with alkyl halides 2a-c proceeded at relatively low temperature and short reaction time. In addition, the synthesized products were obtained in excellent yields. The structure of the new products has been characterized by IR, NMR, and their elemental analyses.